Anti-interleukin 6 receptor antibody treatment in rheumatic disease (original) (raw)
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
- Norihiro Nishimotoa,
- Tadamitsu Kishimotob,
- Kazuyuki Yoshizakia
- aDepartment of Medical Science I, School of Health and Sport Sciences, Osaka University, 2–1 Yamada-oka, Suita City, Osaka 565–0871, Japan, bOsaka University, Osaka
- Dr Nishimoto (norihiro{at}imed3.med.Osaka-u.ac.jp)
Abstract
Interleukin 6 (IL6) is a pleiotropic cytokine with a wide range of biological activities. IL6 transgene into mice gives rise to the abnormalities such as hyper-γ-globulinaemia, thrombocytosis, infiltration of inflammatory cells into the tissues, mesangial cell proliferation of the kidney as well as splenomegaly and lymphadenopathy, which are predictable by the biological functions of IL6 shown in vitro. Continuous overproduction of IL6 is observed in patients with some immune-inflammatory diseases such as Castleman's disease and rheumatoid arthritis that are frequently associated with similar abnormalities to those of IL6 transgenic mice, strongly suggesting the involvement of IL6 in the human diseases. Successful treatment of the model animals for immune-inflammatory diseases with anti-IL6 receptor (IL6R) antibody thus indicates the possible application of IL6 blocking agents to treat the IL6 related immune-inflammatory diseases of humans. In this review, the new therapeutic strategy for Castleman's disease and RA using humanised antibody to human IL6 receptor, MRA, is discussed.
- interleukin 6
- anti-inteleukin 6 receptor antibody
- rheumatoid arthritis
- Castleman's disease
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.